Opinion|Videos|July 8, 2024
Outcomes from NATALEE and MonarchE
Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.
Advertisement
Video content above is prompted by the following:
- (Dr. O’Shaughnessy) How have the MonarchE and NATALEE trials contribute to our understanding of the optimal duration of adjuvant endocrine therapy?
- How might the difference in adjuvant therapy duration between ribociclib and abemaciclib influence discussions around risk-benefit assessments with patients considering CDK4/6i?
- (Dr. Rugo)How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
- Please include a discussion of ribociclib’s MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations.
- Please also include a discussion of capivasertib as a newly approved option based on the CAPItello-291 trial.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
3
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
4
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
5